Compare IDEXX Laboratories, Inc. (IDXX) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Payoneer Global Inc — how do they compare? IDEXX Laboratories, Inc. trades at $554.89 (market cap $44.48B), while Payoneer Global Inc trades at $7.11 (market cap $2.41B). The key difference: IDEXX Laboratories, Inc. is far larger — about 18.5× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | PAYO | |
|---|---|---|
Market Cap | $44.48B | $2.41B |
Sector | Health | Technology |
52-Week High | $766.68 | $7.42 |
52-Week Low | $520.87 | $4.27 |
Enterprise Value | $45.38B | $2.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Payoneer (PAYO) trades at $7.125, up 0.07% today, with a strong technical outlook as moving averages signal bullish momentum. The company reported revenue of $821.16M in 2025, with a net income margin of 8.57%, though earnings have shown volatility with recent beats and misses. Recent news highlights a pending $2.75 billion acquisition by Nuvei, announced June 15, 2026, which has driven significant investor attention and legal scrutiny over the fairness of the $7.40 per share offer.
The acquisition by Nuvei presents a near-term catalyst, but shareholder lawsuits question the deal price. Analyst consensus is bullish with a $8.20 price target, yet execution risks and integration challenges post-acquisition could impact long-term value. Investors should weigh the premium offered against potential standalone growth prospects in the competitive fintech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
